Avecho Biotechnology Limited

Equities

AVE

AU0000047441

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:56 28/05/2024 BST			5-day change	1st Jan Change
0.004 ^AUD	+33.33%		0.00%	+14.29%

05-16	Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial	MT
03-25	Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	MT

Avecho Biotechnology Limited Appoints Matthew Patrick McNamara as Non-Executive Director

January 12, 2020 at 09:37 pm

Avecho Biotechnology Limited announced the appointment of Matthew Patrick McNamara as a Non-Executive Director of the Company, effective 13 January 2020. Matt McNamara has over 30 years' experience in the healthcare and medical sciences sector. Matt has a BSc (Hons) in Molecular Biology and is also a holder of an MBA. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology /investment companies. He is presently a director of Adherium Ltd, SciCapital Pty Ltd. and Grey Innovation Group Pty Ltd.

Latest news about Avecho Biotechnology Limited

Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial	05-16	MT
Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	03-25	MT
Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug	03-14	MT
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial	03-07	MT
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23	CI
Avecho Biotechnology Achieves Two-Year Stability Milestone for CBD Capsule	22/06/23	MT
US Patent Office Allows Avecho Biotechnology's Patent on 'Optimized' Manufacturing Method for Tocopheryl Phosphate Mixture	29/05/23	MT
Avecho Biotechnology Signs Licensing Deal with Arthur Group for Development of Cancer Drugs	22/05/23	MT
Avecho Biotechnology Begins Manufacturing for Oral Cannabidiol Capsules	17/05/23	MT
Avecho Biotechnology Raises AU$2 Million Via Entitlement Offer; Shares Slip 20%	09/05/23	MT
Avecho Biotechnology Conducts Entitlement Offer to Raise $11 Million to Fund Pivotal Phase Iii Clinical Trial	03/04/23	CI
Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt	14/03/23	CI
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Avecho Biotechnology Expands Research Partnership for Cannabidiol Medication	22/02/23	MT
Avecho Biotechnology Limited Announces Ongoing Collaboration with Lambert Initiative	21/02/23	CI
Athenex Pharmaceutical Division Submits Avecho's Vitamin K Injection to US FDA	12/01/23	MT
Athenex Submits Avecho's Phytonadione to FDA Pre-IND	12/01/23	CI
Avecho Biotechnology Secures Ethics Approval for Phase 3 Insomnia Trial	22/12/22	MT
Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia	21/12/22	CI
Avecho Biotechnology Signs Development Deal for TPM-enhanced Ibuprofen Gel for US market; Shares Up 10%	20/12/22	MT
Avecho Biotechnology Limited Signs Development Agreement with Perrigo Company plc	19/12/22	CI
Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study	19/09/22	MT
Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk	19/09/22	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI

Chart Avecho Biotechnology Limited

Duration

Period

More charts

Company Profile

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

Sector

Biotechnology & Medical Research

Calendar

29/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVECHO BIOTECHNOLOGY LIMITED	+14.29%	6.33M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research